Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-10-21 03:05 CEST (UTC+2h)
 

How to waive bridging studies by statistical calculations? [Regulatives / Guidelines]

posted by DavidManteigas - Portugal, 2017-10-12 19:04  - Posting: # 17893
Views: 277

I am not Mr Schütz, but I can't see any statistical calculations that will prevent you from doing a study in Turkey since that seems the opinion of the regulator regardless of any statistics.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,396 Posts in 3,726 Threads, 1,074 registered users;
28 users online (0 registered, 28 guests).

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed